U.S. markets closed
  • S&P 500

    4,422.23
    +10.44 (+0.24%)
     
  • Dow 30

    35,144.71
    +83.16 (+0.24%)
     
  • Nasdaq

    14,840.71
    +3.72 (+0.03%)
     
  • Russell 2000

    2,215.88
    +6.23 (+0.28%)
     
  • Crude Oil

    72.13
    +0.06 (+0.08%)
     
  • Gold

    1,797.70
    -4.10 (-0.23%)
     
  • Silver

    25.26
    +0.03 (+0.11%)
     
  • EUR/USD

    1.1811
    +0.0040 (+0.34%)
     
  • 10-Yr Bond

    1.2760
    -0.0100 (-0.78%)
     
  • GBP/USD

    1.3823
    +0.0069 (+0.50%)
     
  • USD/JPY

    110.3720
    -0.1380 (-0.12%)
     
  • BTC-USD

    39,193.62
    +4,870.00 (+14.19%)
     
  • CMC Crypto 200

    931.97
    +16.48 (+1.80%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

Evofem Biosciences to Present at LD Micro Invitational XI on Tuesday, June 8, 2021

·1 min read

SAN DIEGO, May 25, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that its CEO Saundra Pelletier will present at the 2021 LD Micro Invitational XI on Tuesday, June 8, 2021 at 1:00 p.m. ET (10:00 a.m. PT).

(PRNewsfoto/Evofem Biosciences, Inc.)
(PRNewsfoto/Evofem Biosciences, Inc.)

Pelletier will provide an update on the commercialization of Evofem's hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), the ongoing Phase 3 clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea in women, and other ongoing initiatives.

To pre-register for the presentation, please visit https://ldmicrojune2021.mysequire.com/.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). For more information, please visit evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-ld-micro-invitational-xi-on-tuesday-june-8-2021-301298297.html

SOURCE Evofem Biosciences, Inc.